VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
#Management Changes
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
#Investment
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
#Partners
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
#Investment #Expand
VYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy
#Customers
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
#Investment #Expand
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
#Customers #Expand
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
#Management Changes
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
#Public Trading
Menlo Therapeutics changes name to VYNE Therapeutics
#Management Changes #Acquisition
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
#Customers
Foamix and Menlo announce approval of merger
#Acquisition
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics
#Partners
Israeli dermatology co Foamix merging with US co Menlo
#Acquisition
With 2 NDAs Already Submitted To The FDA, Foamix Sets Itself Up For A Monumental Period (NASDAQ:FOMX)
#Customers
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
#Customers
Dermatology drug development co Foamix raises $64m
#Investment
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
#Customers
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
#Partners
Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
#Customers
Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
#Customers
Foamix Announces Appointment of Sharon Barbari to Board of Directors
#Management Changes
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
#Investment
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
#Management Changes
Foamix Announces Appointment of Anthony Bruno to Board of Directors
#Management Changes
Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
#Customers
Foamix plans $70m offering after acne trial success
#Investment #Expand
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
#Customers
Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
#Customers
Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
#Management Changes
Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
#Management Changes
Allergan and Paratek nail pivotal acne trial, while Foamix makes a late-stage stumble
#Customers
Foamix product approval worth $10m annually
#Partners #Customers
Dermatology drug co Foamix takes on US market
#Investment #Management Changes
Foamix raises $60m in Nasdaq secondary offering
#Investment #Public Trading
Foamix Pharmaceuticals Nasdaq IPO slashed to $40m
#Public Trading